AstraZeneca - Fourth Quarter and Full Year Results 2012
LONDON, Jan. 31, 2013 - Financial performance for the full year
reflects the loss of exclusivity on several brands. At constant
exchange rates (CER), revenue declined by 15 percent and Core EPS
declined by 9 percent
Brilinta/Brilique, Symbicort,...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news